Arix Bioscience Plc Director/PDMR Shareholding (2304I)

TIDMARIX

RNS Number : 2304I

Arix Bioscience Plc

01 December 2022

Arix Bioscience plc

("Company")

PDMR notification & Director Shareholding

The Company announces the annual award of nil cost options to CEO Robert Lyne, which are subject to performance conditions over a three-year assessment period from 1 January 2022 to 31 December 2024 in accordance with the Company's Executive Incentive Plan ("EIP") as disclosed in the Company's Remuneration Policy ("Policy"). Vested Shares are subject to a further two year holding period, as set out in the Policy.

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                                         Robert Lyne 
      -------------------------------------------  ------------------------------------------------------- 
       Reason for the notification 
  2 
      ---------------------------------------------------------------------------------------------------- 
 a)    Position/status                              Chief Executive Officer 
      -------------------------------------------  ------------------------------------------------------- 
 b)    Initial notification                         Initial Notification 
        /Amendment 
      -------------------------------------------  ------------------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ---------------------------------------------------------------------------------------------------- 
 a)    Name                                         Arix Bioscience plc 
      -------------------------------------------  ------------------------------------------------------- 
 b)    LEI                                          213800OVT3AHQCXNIX43 
      -------------------------------------------  ------------------------------------------------------- 
       Details of the transaction(s): section to be repeated for (i) 
  4     each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been conducted 
      ---------------------------------------------------------------------------------------------------- 
 a)    Description of the                           Arix Bioscience plc Ordinary shares of 0.001 
        financial instrument,                        pence each 
        type of instrument 
       Identification code                          GB00BD045071 
 b)    Nature of the transaction                    Award of nil-cost options under the Arix 
                                                     Bioscience plc Executive Incentive Plan ("EIP") 
----  -------------------------------------------  ------------------------------------------------------- 
c)     Price(s) and volume(s)                        Price(s)                   Volume(s) 
      -------------------------------------------   -------------------------  ------------------------- 
    Nil                                                                         636,792 
   --------------------------------------------------------------------------  ------------------------- 
 d)    Aggregated information 
  - Aggregated volume                          N/A (Single Transaction) 
  - Price                                      N/A (Single Transaction) 
 e)    Date of the transaction                      30 November 2022 
 f)    Place of the transaction                     Outside a trading venue 
      -------------------------------------------  ------------------------------------------------------- 
 

For further information please contact:

Kin Company Secretarial Limited, Company Secretary

[phone]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDFLBBLLLXFBQ

(END) Dow Jones Newswires

December 01, 2022 02:45 ET (07:45 GMT)